Fast Five Quiz: Check Your Knowledge of Prostate Cancer

Bradley Schwartz, DO


April 18, 2022

The USPSTF recommends PSA-based screening for prostate cancer in men at 55-69 years of age on an individualized basis. Overtreatment for prostate cancer based solely on PSA test screening results occurs in 20%-50% of cases and may lead to erectile dysfunction, urinary incontinence, bowel control problems, and a small risk for death and serious complications from surgery. Although both DRE- and PSA-based testing are used to screen for prostate cancer, the USPSTF recommendations primarily focus on PSA screening, with or without DRE. The USPSTF has not recommended DRE screening alone for prostate cancer.

Learn more about PSA screening.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.